Senior Director, Revenue Operations

About the Role

Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patients' lives depend on it. At Replimune, we live by our values: United, Audacious, Dedicated, and Candid. People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, and a competitive total rewards program, everyone at Replimune has a unique opportunity to impact the lives of patients, caregivers, and themselves.

The Director of Revenue Operations will work alongside the Chief Accounting Officer as a key leader of the finance team, focusing on the Company’s full commercial launch of its first anticipated product, including managing all aspects of related accounting. This role will oversee and manage revenue accounting, including the month-end close process, SOX control coordination, and ensuring accurate and timely accounting for revenue transactions as the Company scales. The position is based in our Woburn office with a hybrid work arrangement; local candidates are expected to be on-site a minimum of 2 days per week.

Responsibilities

• Develop and implement the Company’s first Order-to-Cash business processes by working with internal and external stakeholders to support the anticipated product launch.
• Work cross-functionally to implement the Order-to-Cash process within Oracle, collaborating with a third-party Oracle implementor, including system integration with the third-party logistics provider.
• Review relevant contracts, including 3PL and specialty distribution/pharmacy agreements, to ensure proper accounting.
• Build and maintain gross-to-net revenue and inventory accounting policies and practices to ensure revenue and inventory transactions are properly recorded.
• Develop necessary revenue and inventory reporting within Oracle for month-end close and support business analytics.
• Implement, develop, and maintain robust internal controls related to the revenue and inventory process, including key controls around the gross-to-net calculation, to ensure compliance with US GAAP, other regulations, and internal financial policies.
• Work with the accounting team through the month-end close process, including creation and review of journal entries, reconciliations, and analysis for product revenue, gross-to-net, inventory, and accounts receivable.

Qualifications

• Strong communication and interpersonal skills to own processes and collaborate cross-functionally in developing accounting processes for the Company’s first commercial launch.
• Demonstrated ability to prepare and communicate complex technical issues and analysis to internal and external stakeholders, including management and external auditors.
• Bachelor’s Degree in Business, Finance, Accounting, or an equivalent qualification.
• 10-15 years of experience in accounting/finance within the biotechnology or life sciences industries, with emphasis on commercial product launch.
• Certified Public Accountant (CPA) and Big 4 experience preferred.

Pay

For this role, the anticipated base pay range is $221,000–$286,000. The exact base pay offered will depend on various factors, including the candidate’s qualifications, skills, and experience, as well as organizational needs. Base pay is only one part of the total compensation package, which also includes an annual performance incentive bonus, new hire equity, ongoing performance-based equity, medical/dental/vision insurance, a 401k match, flexible time off, and paid holidays including a year-end shutdown.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone designed to maximize immunogenic cell death and induce a systemic anti-tumor immune response. The RPx platform is intended to provide dual local and systemic activity, combining direct virus-mediated tumor killing with the release of tumor-derived antigens and alteration of the tumor microenvironment to ignite a strong, durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatments, enabling development alone or in combination with other therapies.